Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 157

1.

Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer.

Tanyi JL, Bobisse S, Ophir E, Tuyaerts S, Roberti A, Genolet R, Baumgartner P, Stevenson BJ, Iseli C, Dangaj D, Czerniecki B, Semilietof A, Racle J, Michel A, Xenarios I, Chiang C, Monos DS, Torigian DA, Nisenbaum HL, Michielin O, June CH, Levine BL, Powell DJ Jr., Gfeller D, Mick R, Dafni U, Zoete V, Harari A, Coukos G, Kandalaft LE.

Sci Transl Med. 2018 Apr 11;10(436). pii: eaao5931. doi: 10.1126/scitranslmed.aao5931.

PMID:
29643231
2.

Pan-SRC kinase inhibition blocks B-cell receptor oncogenic signaling in non-Hodgkin lymphoma.

Battistello E, Katanayeva N, Dheilly E, Tavernari D, Donaldson MC, Bonsignore L, Thome-Miazza M, Christie AL, Murakami MA, Michielin O, Ciriello G, Zoete V, Oricchio E.

Blood. 2018 Mar 22. pii: blood-2017-10-809210. doi: 10.1182/blood-2017-10-809210. [Epub ahead of print]

PMID:
29567799
3.

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.

Bobisse S, Genolet R, Roberti A, Tanyi JL, Racle J, Stevenson BJ, Iseli C, Michel A, Le Bitoux MA, Guillaume P, Schmidt J, Bianchi V, Dangaj D, Fenwick C, Derré L, Xenarios I, Michielin O, Romero P, Monos DS, Zoete V, Gfeller D, Kandalaft LE, Coukos G, Harari A.

Nat Commun. 2018 Mar 15;9(1):1092. doi: 10.1038/s41467-018-03301-0.

4.

Quantification of the next-generation oral anti-tumor drugs dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib and two metabolites in human plasma by liquid chromatography-tandem mass spectrometry.

Cardoso E, Mercier T, Wagner AD, Homicsko K, Michielin O, Ellefsen-Lavoie K, Cagnon L, Diezi M, Buclin T, Widmer N, Csajka C, Decosterd L.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Apr 15;1083:124-136. doi: 10.1016/j.jchromb.2018.02.008. Epub 2018 Feb 8.

PMID:
29544202
5.

Comment on "MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma".

Voruz S, Martins F, Cairoli A, Naveiras O, Homicsko K, Missiaglia E, de Leval L, Bisig B, Michielin O, Blum S.

Haematologica. 2018 Mar;103(3):e130. doi: 10.3324/haematol.2017.186932. No abstract available.

6.

ECCO essential requirements for quality cancer care: Melanoma.

Wouters MW, Michielin O, Bastiaannet E, Beishon M, Catalano O, Del Marmol V, Delgado-Bolton R, Dendale R, Trill MD, Ferrari A, Forsea AM, Kreckel H, Lövey J, Luyten G, Massi D, Mohr P, Oberst S, Pereira P, Prata JPP, Rutkowski P, Saarto T, Sheth S, Spurrier-Bernard G, Vuoristo MS, Costa A, Naredi P.

Crit Rev Oncol Hematol. 2018 Feb;122:164-178. doi: 10.1016/j.critrevonc.2017.12.020. Epub 2018 Jan 2. Review.

7.

Benefit of the nivolumab and ipilimumab combination in pretreated advanced melanoma.

Tétu P, Mangana J, Dummer R, Dutriaux C, Beneton N, Dalle S, Meyer N, Oriano B, Michielin O, Lebbe C.

Eur J Cancer. 2018 Apr;93:147-149. doi: 10.1016/j.ejca.2018.01.062. Epub 2018 Feb 12. No abstract available.

PMID:
29449059
8.

ESCMID Study Group for Infections in Compromised Hosts (ESGICH) consensus document on the safety of targeted and biological therapies: an infectious diseases perspective-immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine 1-phosphate receptor modulators and proteasome inhibitors.

Redelman-Sidi G, Michielin O, Cervera C, Ribi C, Aguado JM, Fernández-Ruiz M, Manuel O.

Clin Microbiol Infect. 2018 Feb 7. pii: S1198-743X(18)30148-4. doi: 10.1016/j.cmi.2018.01.030. [Epub ahead of print] Review.

PMID:
29427804
9.

Response to MEK inhibition with trametinib and tyrosine kinase inhibition with imatinib in multifocal histiocytic sarcoma.

Voruz S, Cairoli A, Naveiras O, de Leval L, Missiaglia E, Homicsko K, Michielin O, Blum S.

Haematologica. 2018 Jan;103(1):e39-e41. doi: 10.3324/haematol.2017.179150. Epub 2017 Nov 2. No abstract available.

10.

T cell receptor alpha variable 12-2 bias in the immunodominant response to Yellow fever virus.

Bovay A, Zoete V, Dolton G, Bulek AM, Cole DK, Rizkallah PJ, Fuller A, Beck K, Michielin O, Speiser DE, Sewell AK, Fuertes Marraco SA.

Eur J Immunol. 2018 Feb;48(2):258-272. doi: 10.1002/eji.201747082. Epub 2017 Dec 11.

11.

Mutant CTNNB1 and histological heterogeneity define metabolic subtypes of hepatoblastoma.

Crippa S, Ancey PB, Vazquez J, Angelino P, Rougemont AL, Guettier C, Zoete V, Delorenzi M, Michielin O, Meylan E.

EMBO Mol Med. 2017 Nov;9(11):1589-1604. doi: 10.15252/emmm.201707814.

12.

Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma.

Fankhauser M, Broggi MAS, Potin L, Bordry N, Jeanbart L, Lund AW, Da Costa E, Hauert S, Rincon-Restrepo M, Tremblay C, Cabello E, Homicsko K, Michielin O, Hanahan D, Speiser DE, Swartz MA.

Sci Transl Med. 2017 Sep 13;9(407). pii: eaal4712. doi: 10.1126/scitranslmed.aal4712.

PMID:
28904226
13.

Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy.

Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, Olszanski AJ, Malvehy J, Cebon J, Fernandez E, Kirkwood JM, Gajewski TF, Chen L, Gorski KS, Anderson AA, Diede SJ, Lassman ME, Gansert J, Hodi FS, Long GV.

Cell. 2017 Sep 7;170(6):1109-1119.e10. doi: 10.1016/j.cell.2017.08.027.

PMID:
28886381
14.

A practical guide to the handling and administration of talimogene laherparepvec in Europe.

Harrington KJ, Michielin O, Malvehy J, Pezzani Grüter I, Grove L, Frauchiger AL, Dummer R.

Onco Targets Ther. 2017 Aug 2;10:3867-3880. doi: 10.2147/OTT.S133699. eCollection 2017. Review.

15.

The Binding Mode of N-Hydroxyamidines to Indoleamine 2,3-Dioxygenase 1 (IDO1).

Röhrig UF, Zoete V, Michielin O.

Biochemistry. 2017 Aug 22;56(33):4323-4325. doi: 10.1021/acs.biochem.7b00586. Epub 2017 Jul 27.

PMID:
28731684
16.

The T-Cell Receptor Can Bind to the Peptide-Bound Major Histocompatibility Complex and Uncomplexed β2-Microglobulin through Distinct Binding Sites.

Merkle PS, Irving M, Hongjian S, Ferber M, Jørgensen TJD, Scholten K, Luescher I, Coukos G, Zoete V, Cuendet MA, Michielin O, Rand KD.

Biochemistry. 2017 Aug 1;56(30):3945-3961. doi: 10.1021/acs.biochem.7b00385. Epub 2017 Jul 19.

PMID:
28671821
17.

Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.

Spodzieja M, Lach S, Iwaszkiewicz J, Cesson V, Kalejta K, Olive D, Michielin O, Speiser DE, Zoete V, Derré L, Rodziewicz-Motowidło S.

PLoS One. 2017 Jun 8;12(6):e0179201. doi: 10.1371/journal.pone.0179201. eCollection 2017.

18.

Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.

Mangana J, Cheng PF, Kaufmann C, Amann VC, Frauchiger AL, Stögner V, Held U, von Moos R, Michielin O, Braun RP, Levesque MP, Goldinger SM, Dummer R.

Melanoma Res. 2017 Aug;27(4):358-368. doi: 10.1097/CMR.0000000000000359.

19.
20.

Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors.

Dummer R, Hoeller C, Gruter IP, Michielin O.

Cancer Immunol Immunother. 2017 Jun;66(6):683-695. doi: 10.1007/s00262-017-1967-1. Epub 2017 Feb 25. Review.

21.

Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope.

Baumgaertner P, Costa Nunes C, Cachot A, Maby-El Hajjami H, Cagnon L, Braun M, Derré L, Rivals JP, Rimoldi D, Gnjatic S, Abed Maillard S, Marcos Mondéjar P, Protti MP, Romano E, Michielin O, Romero P, Speiser DE, Jandus C.

Oncoimmunology. 2016 Sep 9;5(10):e1216290. eCollection 2016.

22.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

23.

In-Vivo Detection and Tracking of T Cells in Various Organs in a Melanoma Tumor Model by 19F-Fluorine MRS/MRI.

Gonzales C, Yoshihara HA, Dilek N, Leignadier J, Irving M, Mieville P, Helm L, Michielin O, Schwitter J.

PLoS One. 2016 Oct 13;11(10):e0164557. doi: 10.1371/journal.pone.0164557. eCollection 2016.

24.

1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).

Röhrig UF, Majjigapu SR, Caldelari D, Dilek N, Reichenbach P, Ascencao K, Irving M, Coukos G, Vogel P, Zoete V, Michielin O.

Bioorg Med Chem Lett. 2016 Sep 1;26(17):4330-3. doi: 10.1016/j.bmcl.2016.07.031. Epub 2016 Jul 16.

PMID:
27469130
25.

Debio 0617B Inhibits Growth of STAT3-Driven Solid Tumors through Combined Inhibition of JAK, SRC, and Class III/V Receptor Tyrosine Kinases.

Murone M, Vaslin Chessex A, Attinger A, Ramachandra R, Shetty SJ, Daginakatte G, Sengupta S, Marappan S, Dhodheri S, Rigotti S, Bachhav Y, Brienza S, Traxler P, Lang M, Aguet M, Zoete V, Michielin O, Nicholas C, Johnson FM, Ramachandra M, McAllister A.

Mol Cancer Ther. 2016 Oct;15(10):2334-2343. Epub 2016 Jul 20.

26.

[Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].

Martins F, Orcurto A, Michielin O, Coukos G.

Rev Med Suisse. 2016 May 18;12(519):989-93. French.

PMID:
27424426
27.

SwissSimilarity: A Web Tool for Low to Ultra High Throughput Ligand-Based Virtual Screening.

Zoete V, Daina A, Bovigny C, Michielin O.

J Chem Inf Model. 2016 Aug 22;56(8):1399-404. doi: 10.1021/acs.jcim.6b00174. Epub 2016 Jul 19.

PMID:
27391578
28.

Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma.

Hoeller C, Michielin O, Ascierto PA, Szabo Z, Blank CU.

Cancer Immunol Immunother. 2016 Sep;65(9):1015-34. doi: 10.1007/s00262-016-1860-3. Epub 2016 Jul 2. Review.

29.

Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas.

Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M, Iwaszkiewicz J, Fataccioli V, Bisig B, Roberti A, Grewal J, Bruneau J, Fabiani B, Martin A, Bonnet C, Michielin O, Jais JP, Figeac M, Bernard OA, Delorenzi M, Haioun C, Tournilhac O, Thome M, Gascoyne RD, Gaulard P, de Leval L.

Blood. 2016 Sep 15;128(11):1490-502. doi: 10.1182/blood-2016-02-698977. Epub 2016 Jul 1.

30.

Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma.

Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, Seplyarskiy VB, Sharpe HJ, McKee T, Letourneau A, Ribaux PG, Popadin K, Basset-Seguin N, Ben Chaabene R, Santoni FA, Andrianova MA, Guipponi M, Garieri M, Verdan C, Grosdemange K, Sumara O, Eilers M, Aifantis I, Michielin O, de Sauvage FJ, Antonarakis SE, Nikolaev SI.

Nat Genet. 2016 Apr;48(4):398-406. doi: 10.1038/ng.3525. Epub 2016 Mar 7.

PMID:
26950094
31.

Design and Validation of a Novel Generic Platform for the Production of Tetravalent IgG1-like Bispecific Antibodies.

Golay J, Choblet S, Iwaszkiewicz J, Cérutti P, Ozil A, Loisel S, Pugnière M, Ubiali G, Zoete V, Michielin O, Berthou C, Kadouche J, Mach JP, Duonor-Cérutti M.

J Immunol. 2016 Apr 1;196(7):3199-211. doi: 10.4049/jimmunol.1501592. Epub 2016 Feb 26.

32.

The updated Swiss guidelines 2016 for the treatment and follow-up of cutaneous melanoma.

Dummer R, Siano M, Hunger RE, Lindenblatt N, Braun R, Michielin O, Mihic-Probst D, von Moos R, Najafi Y, Guckenberger M, Arnold A.

Swiss Med Wkly. 2016 Feb 22;146:w14279. doi: 10.4414/smw.2016.14279. eCollection 2016. Review.

33.

STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.

Demaria O, De Gassart A, Coso S, Gestermann N, Di Domizio J, Flatz L, Gaide O, Michielin O, Hwu P, Petrova TV, Martinon F, Modlin RL, Speiser DE, Gilliet M.

Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13. doi: 10.1073/pnas.1512832112. Epub 2015 Nov 25.

34.

Attracting cavities for docking. Replacing the rough energy landscape of the protein by a smooth attracting landscape.

Zoete V, Schuepbach T, Bovigny C, Chaskar P, Daina A, Röhrig UF, Michielin O.

J Comput Chem. 2016 Feb 5;37(4):437-47. doi: 10.1002/jcc.24249. Epub 2015 Nov 12.

35.

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.

Legat A, Maby-El Hajjami H, Baumgaertner P, Cagnon L, Abed Maillard S, Geldhof C, Iancu EM, Lebon L, Guillaume P, Dojcinovic D, Michielin O, Romano E, Berthod G, Rimoldi D, Triebel F, Luescher I, Rufer N, Speiser DE.

Clin Cancer Res. 2016 Mar 15;22(6):1330-40. doi: 10.1158/1078-0432.CCR-15-1212. Epub 2015 Oct 23.

36.

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?

Mangana J, Cheng PF, Schindler K, Weide B, Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner M, Moch H, Michielin O, Garbe C, Hauschild A, Hoeller C, Dummer R, Goldinger SM.

PLoS One. 2015 Oct 1;10(10):e0139438. doi: 10.1371/journal.pone.0139438. eCollection 2015.

37.

[New melanoma immunotherapies: mechanisms of action, efficiency and management of toxicities].

Moura B, Homicsko K, Berthod G, Cerottini JP, Guggisberg D, Gaide O, Maillard MH, Michielin O.

Rev Med Suisse. 2015 May 20;11(475):1108, 1110-4. Review. French.

PMID:
26152085
38.

Gaining momentum: New options and opportunities for the treatment of advanced melanoma.

Michielin O, Hoeller C.

Cancer Treat Rev. 2015 Sep;41(8):660-70. doi: 10.1016/j.ctrv.2015.05.012. Epub 2015 Jun 4. Review.

PMID:
26096079
39.

Challenges in the Discovery of Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.

Röhrig UF, Majjigapu SR, Vogel P, Zoete V, Michielin O.

J Med Chem. 2015 Dec 24;58(24):9421-37. doi: 10.1021/acs.jmedchem.5b00326. Epub 2015 May 26. Review.

PMID:
25970480
40.

Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients.

Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P, Speiser DE.

Proc Natl Acad Sci U S A. 2015 May 12;112(19):6140-5. doi: 10.1073/pnas.1417320112. Epub 2015 Apr 27.

41.

iLOGP: a simple, robust, and efficient description of n-octanol/water partition coefficient for drug design using the GB/SA approach.

Daina A, Michielin O, Zoete V.

J Chem Inf Model. 2014 Dec 22;54(12):3284-301. doi: 10.1021/ci500467k. Epub 2014 Nov 25.

PMID:
25382374
42.

Pulmonary sarcoid-like granulomatosis after multiple vaccinations of a long-term surviving patient with metastatic melanoma.

Bordry N, Costa-Nunes CM, Cagnon L, Gannon PO, Abed-Maillard S, Baumgaertner P, Murray T, Letovanec I, Lazor R, Bouchaab H, Rufer N, Romano E, Michielin O, Speiser DE.

Cancer Immunol Res. 2014 Dec;2(12):1148-53. doi: 10.1158/2326-6066.CIR-14-0143. Epub 2014 Oct 2.

43.

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-Pietras D, Welters MJ, van der Burg S, Kapiteijn E, Michielin O, Romano E, Linnemann C, Speiser D, Blank C, Haanen JB, Schumacher TN.

Sci Transl Med. 2014 Sep 17;6(254):254ra128. doi: 10.1126/scitranslmed.3008918.

44.

Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.

Peters S, Bouchaab H, Zimmerman S, Bucher M, Gaide O, Letovanec I, Homicsko K, Michielin O.

Melanoma Res. 2014 Oct;24(5):496-500. doi: 10.1097/CMR.0000000000000055.

PMID:
25185693
45.

Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Röhrig UF, Majjigapu SR, Chambon M, Bron S, Pilotte L, Colau D, Van den Eynde BJ, Turcatti G, Vogel P, Zoete V, Michielin O.

Eur J Med Chem. 2014 Sep 12;84:284-301. doi: 10.1016/j.ejmech.2014.06.078. Epub 2014 Jul 10.

PMID:
25036789
46.

A WXW motif is required for the anticancer activity of the TAT-RasGAP317-326 peptide.

Barras D, Chevalier N, Zoete V, Dempsey R, Lapouge K, Olayioye MA, Michielin O, Widmann C.

J Biol Chem. 2014 Aug 22;289(34):23701-11. doi: 10.1074/jbc.M114.576272. Epub 2014 Jul 9.

47.

[Together, towards precise oncology!].

Coukos G, Michielin O, Dietrich P, Aapro M.

Rev Med Suisse. 2014 May 21;10(431):1099-100. French. No abstract available.

PMID:
24941676
48.

[Genomics medicine and oncology].

Michielin O, Coukos G.

Praxis (Bern 1994). 2014 May 7;103(10):591-6. doi: 10.1024/1661-8157/a001659. French.

PMID:
24800772
49.

SwissTargetPrediction: a web server for target prediction of bioactive small molecules.

Gfeller D, Grosdidier A, Wirth M, Daina A, Michielin O, Zoete V.

Nucleic Acids Res. 2014 Jul;42(Web Server issue):W32-8. doi: 10.1093/nar/gku293. Epub 2014 May 3.

50.

Fifteen years SIB Swiss Institute of Bioinformatics: life science databases, tools and support.

Stockinger H, Altenhoff AM, Arnold K, Bairoch A, Bastian F, Bergmann S, Bougueleret L, Bucher P, Delorenzi M, Lane L, Le Mercier P, Lisacek F, Michielin O, Palagi PM, Rougemont J, Schwede T, von Mering C, van Nimwegen E, Walther D, Xenarios I, Zavolan M, Zdobnov EM, Zoete V, Appel RD.

Nucleic Acids Res. 2014 Jul;42(Web Server issue):W436-41. doi: 10.1093/nar/gku380. Epub 2014 May 3.

Supplemental Content

Loading ...
Support Center